The Polymath Investor Substack (polymathinvestor.com) — stocks and cross-disciplinary investing ideas, incl. guest company features from Robert Gignac / Forterra Investment Management. Running synthesis of processed posts, with per-post breakdowns and a stock index.
BioSyent (TSXV: RX) — an asset-light Canadian in-licensing pharma: it never discovers a drug, so there is no research risk and no patent cliff, only commercial execution — a formula good for 63 consecutive profitable quarters and 14-year CAGRs of 19.6% revenue / 17.7% EPS with the share count down 20%. The re-rating case is concentration dilution: FeraMAX has fallen from ~70% to ~40% of revenue as two new pillars arrived — the March 2026 $25.5M Oral Science acquisition (6.3x TTM EBITDA, <5x adjusted for working capital; >6,000 dental clinics, ~40% of Canada's, $31.2M 2025 revenue compounding at 15%) of which only one month ($2.98M) has printed in reported results, and Thyconvi, Canada's first liquid levothyroxine, in-licensed for a EUR 50,000 upfront and Health Canada-approved May 2026, underwritten on private pay only with zero provincial reimbursement in the base case ($10M peak guided; authors model $5-20M). CEO Rene Goehrum owns ~20% (a 72-bagger since he took over in 1999); free optionality in PerioMonitor out-licensing, formulary access and further M&A. ~8.5x 2027E EV/EBITDA vs a 10-12x re-rate target = $22-30 base-case fair value vs $14.50. Watch-points: Accrufer (Kye Pharmaceuticals), Canada's first prescription oral iron, whose prescription status unlocks drug-plan coverage FeraMAX's natural-health-product classification cannot access; Oral Science integration/key-person and Curaden dependency; and ~5,000 shares/day liquidity with one analyst covering. Held by Forterra and both authors.
In one line: Buy small, boring, owner-operated compounders whose business model removes the risk you can't analyse — then wait. The Polymath Investor writes up single names at length, and the first processed piece (a guest company feature co-written with Robert Gignac of Forterra Investment Management) is the template: an asset-light Canadian microcap that licenses proven products instead of discovering them, so there is no research risk and no patent cliff — only execution, which is the one thing a management team's track record can actually tell you about.
Business model before valuation. The first screen is structural: which risks does the company not carry? An in-licensing pharma with no R&D line and no patent cliff converts an un-analysable scientific bet into an analysable sales-execution bet — and 63 consecutive profitable quarters is the proof the model works across a cycle, not a back-test.
Concentration dilution is the catalyst. The names to hunt are the ones the market still discounts as one-trick ponies while the single-product share is actively falling because new pillars are being added — not because the core is shrinking. The edge is the reporting lag: a company can be structurally diversified for several quarters before a single screen reflects it.
Underwrite so the base case can't be wrong in the expensive direction. Prefer plans that explicitly exclude the contested variable (government reimbursement, an out-licensing deal, a further acquisition) and keep every excluded branch on a separate free-option list. Conversely, hunt for asymmetry on the entry side — a EUR 50,000 upfront fee against one of a country's largest chronic prescription categories is an option premium, not a capital commitment.
Owner-operators, verified by the share count. A CEO with ~20% of the company is the screen; the proof is a decade-plus of revenue and EPS compounding with a falling share count, and a dividend still rising and buybacks still running through the largest acquisition in company history.
Illiquidity is the source of the edge, not a reason to pass — one sell-side analyst and a few thousand shares a day is precisely why the mispricing survives. The corollary is honest: the horizon is years, position size is set against daily volume rather than conviction, and price in a thin book says little about the business.
Macro-indifference by design. Where oil, rates, tariffs and consumer credit plausibly change nothing about next year's revenue, the whole thesis collapses to execution — and the research budget goes to management, product mix and the acquisition multiple instead of forecasting the cycle.
Disclosure discipline. Guest features state positions plainly and impose a no-trade window after publication (ten business days on the BioSyent piece) — the honest version of writing up a name too thin to trade around.
Posts
One dated page per post — each has its full stock table, talking points, and the saved text. Newest first.